Nasobec (Beclometasone Dipropionate)

Beclometasone Dipropionate, the active ingredient in Nasobec, is a corticosteroid presented as a nasal spray for endosinusial use. It reduces inflammation of the nasal mucosa and is employed to manage allergic and non‑allergic nasal conditions in both adults and children.

GNH USA supplies Nasobec as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Beclometasone Dipropionate nasal spray acts on inflammatory pathways of the nasal mucosa to relieve symptoms of several upper‑respiratory conditions.

- Allergic rhinitis: decreases nasal congestion, sneezing, itching and rhinorrhoea. - Nasal polyps: helps shrink polyps and improves nasal airflow. - Non‑allergic rhinitis: reduces mucosal inflammation and post‑nasal drip.

Adverse reactions may occur with nasal administration of beclometasone dipropionate.

Common Side Effects: - Nasal irritation or burning sensation. - Dryness of the nasal passages. - Epistaxis (nosebleeds). - Headache. - Altered taste or bitter after‑taste. - Throat irritation or cough.

Serious or Rare Side Effects: - Fungal infection of the nasal mucosa. - Severe or persistent epistaxis. - Vision changes such as cataract formation. - Adrenal suppression with prolonged high‑dose use. - Anaphylactic or severe allergic reactions. - Nasal septum perforation.

Use Nasobec only under medical supervision and follow prescribed duration.

- Prolonged use: monitor for signs of systemic corticosteroid effects. - Existing infections: avoid if active nasal or sinus infection is present. - Glaucoma or cataract: use with caution and seek ophthalmologic review. - Diabetes mellitus: monitor blood glucose as local steroids may affect control. - Known hypersensitivity: discontinue if allergic reaction occurs. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Beclometasone Dipropionate may interact with other medicines that affect corticosteroid metabolism or increase immunosuppression.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): may raise systemic exposure. - Concurrent systemic or intranasal corticosteroids: increase risk of systemic side effects. - Immunosuppressive agents: heightened risk of infection.

Moderate Interactions (Monitor Closely): - Antihistamines: may enhance sedative effects in sensitive individuals. - Antiviral nasal sprays (e.g., interferon): monitor for additive local irritation. - Antifungal nasal preparations: assess for overlapping mucosal effects.